"Marge" Bests Herceptin
The treatment of HER2+ breast cancer was revolutionized by approval of Roche's (RHHBY) Herceptin (trastuzumab) in the late 90s. In the past two decades, Herceptin has saved thousands of lives and registered over $75 billion in global sales.
Since that time, HER2 has become one of the most drugged targets in oncology, with approvals of the antibody Perjeta/pertuzumab (Roche), the antibody-drug-conjugate Kadcyla/ado-trastuzumab emastine (Roche), the HER2/EGFR kinase inhibitor Tykerb/lapatinib (GSK), and Nerlynx/neratinib (PBYI). In addition to the approved drugs targeting HER2, other therapies are currently in clinical development,